Literature DB >> 1590452

Effect of microvascular rarefaction on tissue oxygen delivery in hypertension.

A S Greene1, P J Tonellato, Z Zhang, J H Lombard, A W Cowley.   

Abstract

A mathematical model of oxygen transport in tissue was used to analyze the effects of microvessel rarefaction and nonhomogeneous oxygen consumption on tissue oxygen distribution. The model was based on the diffusion equation with a nonhomogeneous consumption term. Solutions were computed for several configurations of vessel and oxygen sink distributions on a finite domain using the finite element method. A microcirculatory unit consisting of a tissue slice of 100-microns depth and 40-microns width was chosen. Symmetry boundary conditions were applied so that the entire tissue consisted of a series of such microvascular units placed side by side. The boundary condition at the surface of the unit was chosen to simulate a tissue suffusion experiment in which the suffusion oxygen was varied from 0 to 37 mmHg. Results of the model, which were compared with direct measurements with oxygen microelectrodes, indicate that vascular oxygen delivery strongly dominates the tissue oxygen field for suffusion PO2 values of less than 20 mmHg, whereas above this level tissue oxygen is dominated by the suffusion PO2. Reduction of vessel density within the tissue was found to have the largest effect on tissue oxygen levels at low suffusion oxygen. Finally, under some configurations of oxygen sources (vessels) and sinks (mitochondria), extremely low PO2 levels may exist within the area of high consumption, which could limit the metabolic activity of the tissue.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1590452     DOI: 10.1152/ajpheart.1992.262.5.H1486

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  13 in total

1.  NRF2 activation with Protandim attenuates salt-induced vascular dysfunction and microvascular rarefaction.

Authors:  Jessica R C Priestley; Katie E Fink; Joe M McCord; Julian H Lombard
Journal:  Microcirculation       Date:  2019-06-19       Impact factor: 2.628

2.  A nonlinear model for myogenic regulation of blood flow to bone: equilibrium states and stability characteristics.

Authors:  T P Harrigan
Journal:  Ann Biomed Eng       Date:  1996 Mar-Apr       Impact factor: 3.934

3.  Toward modeling the human physionome.

Authors:  J B Bassingthwaighte
Journal:  Adv Exp Med Biol       Date:  1995       Impact factor: 2.622

Review 4.  ABO-compatible liver allograft antibody-mediated rejection: an update.

Authors:  Anthony J Demetris; Adriana Zeevi; Jacqueline G O'Leary
Journal:  Curr Opin Organ Transplant       Date:  2015-06       Impact factor: 2.640

Review 5.  Microvascular angiogenesis and the renin-angiotensin system.

Authors:  Andrew S Greene; Sandra L Amaral
Journal:  Curr Hypertens Rep       Date:  2002-02       Impact factor: 5.369

6.  Angiogenesis in mesenteric microvascular networks from spontaneously hypertensive versus normotensive rats.

Authors:  Ming Yang; Mario Aragon; Walter L Murfee
Journal:  Microcirculation       Date:  2011-10       Impact factor: 2.628

7.  Metabolic effects of prazosin on skeletal muscle insulin resistance in glucocorticoid-treated male rats.

Authors:  Emily C Dunford; Erin R Mandel; Sepideh Mohajeri; Tara L Haas; Michael C Riddell
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2016-11-09       Impact factor: 3.619

8.  Mathematical analysis of type-I and type-IIb muscle fiber force generation in renal hypertension.

Authors:  M J Rieder; D M O'Drobinak; P J Tonellato; A S Greene
Journal:  Ann Biomed Eng       Date:  1996 Jul-Aug       Impact factor: 3.934

9.  Insulin resistance and vasodilation in essential hypertension. Studies with adenosine.

Authors:  A Natali; R Bonadonna; D Santoro; A Q Galvan; S Baldi; S Frascerra; C Palombo; S Ghione; E Ferrannini
Journal:  J Clin Invest       Date:  1994-10       Impact factor: 14.808

Review 10.  Theoretical models of microvascular oxygen transport to tissue.

Authors:  Daniel Goldman
Journal:  Microcirculation       Date:  2008-11       Impact factor: 2.628

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.